Omkar Pharmachem reported a net loss of ₹1.00 lakh for the quarter ended June 30, 2026, marking a shift from the ₹1.50 lakh profit recorded in the immediately preceding quarter ended March 31, 2026. The Board of Directors approved the unaudited standalone financial results on August 13, 2026. The results were reviewed by the audit committee and in accordance with Standard on Review Engagement (SRE) 2410 by Dipal R. Shah & Co., Chartered Accountants.

The company generated zero income from core operations, with net sales remaining at nil. Total income from operations was confined to ₹9.00 lakh from other operating income, which remained stable compared to the prior quarter but fell from ₹13.50 lakh in the same period last year. Other income was nil for the current quarter, compared to ₹0.30 lakh in the previous quarter.

Financial Performance

Total expenses increased to ₹10.00 lakh from ₹7.35 lakh in the previous quarter. This rise was largely attributable to an increase in other expenses, which jumped to ₹4.82 lakh from ₹2.13 lakh. Employee benefits remained steady at ₹5.14 lakh, while depreciation and amortization costs decreased slightly to ₹0.04 lakh from ₹0.08 lakh. There were no exceptional items or tax expenses reported for the quarter.

What the Numbers Show

The financial data reveals a complete absence of operational revenue generation during the quarter. With net sales at zero, the company’s ability to cover fixed costs relied entirely on non-operating income streams. The widening loss despite stable other operating income highlights the pressure from variable other expenses, which more than doubled compared to the previous quarter, eroding the thin margin previously supported by lower cost structures.

Omkar Pharmachem Limited returned to profitability in the financial year ended March 31, 2026, reporting a net profit of ₹12.18 lakh, a reversal from the previous year's performance. The company recorded a total comprehensive income of ₹2720.61 lakh for the year, significantly bolstered by other comprehensive income of ₹2708.43 lakh. The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 30, 2026.

For the quarter ended March 31, 2026, the company reported a profit of ₹1.50 lakh, compared to a loss of ₹2.15 lakh in the same period of the previous year. Total income for the quarter stood at ₹9.30 lakh, while total expenses were ₹7.35 lakh. The statutory auditor, M/s. Dipal R. Shah & Co., issued an unmodified opinion on the standalone financial results, confirming compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The balance sheet as of March 31, 2026, shows total assets at ₹3669.04 lakh, a substantial increase from ₹960.33 lakh in the previous year. This growth is primarily attributed to other investments, which rose to ₹3638.43 lakh from ₹930.00 lakh. Equity attributable to the owners of the company stood at ₹3663.98 lakh, compared to ₹943.37 lakh in the prior year. The company maintained a debt-free status with no borrowings recorded under non-current or current financial liabilities.

Cash flow from operating activities improved to ₹22.84 lakh in FY26 from ₹24.35 lakh in the previous year. The company generated cash primarily through operations and saw a net increase in cash and cash equivalents of ₹10.79 lakh, bringing the closing balance to ₹21.73 lakh. Investing activities remained neutral with no net cash used, while financing activities resulted in a net outflow of ₹12.06 lakh, largely due to the repayment of short-term borrowings.

Financial Performance Summary

Assets and Liabilities